Schott has announced further investments in its pharma business, for additional capacity in Hungary to produce prefillable glass syringes.
“The added capacity will greatly benefit the global market and strengthen supply security for major pharmaceutical companies and contract manufacturing organisations,” said Andreas Reisse, Executive VP of Schott’s Pharma business unit. The investment is supported by the local government with about €9m ($9.9m). The expansion is scheduled for completion in 2024 and will create approximately 120 jobs.
Typically, drugs enter the market in a vial and a single-use syringe is used to extract and administer them. In the mid-to-long term, they may be stored in prefilled syringes to simplify the injection process for healthcare workers and increase dosing accuracy for the patient, as the syringe is already readily prepared.
“High-quality prefillable syringes are designed to ease the administration process, ultimately enhancing patient safety,” said Christian Helbig, Head of Glass Syringes at Schott’s pharma business unit. “Our borosilicate glass PFS are used to safely store a wide range of drugs, including vaccines and biologics.”
The Hungarian site in Lukácsháza already supplies drug containment systems to the global pharmaceutical industry and provides enough space for further capacity expansions to follow.
